Over the last several years, new therapeutic targets have emerged in immunotherapy,
particularly the immune checkpoint pathways. Blocking inhibitory pathways via monoclonal …

Abstract Treatment of lung cancer remains a challenge, and lung cancer is still the leading
cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but …

Recent breakthroughs in translating the early development of immunomodulatory antibodies
into the clinic, notably with the anti–cytotoxic T-lymphocyte antigen-4 antibody, ipilimumab …

Immunotherapy has emerged in recent years as a promising therapeutic approach in lung
cancer. Two approaches are of particular interest: immune checkpoint inhibition, which aims …

Lung carcinoma is the leading cause of death by cancer worldwide. When possible, surgery
is the best treatment strategy for patients with non–small-cell lung cancer. However, even …

Many decades in the making, immunotherapy has demonstrated its ability to produce
durable responses in several cancer types. In the last decade, immunotherapy has shown …

Introduction. Immunotherapy has become an increasingly important therapeutic strategy for
those with cancer, with phase III studies demonstrating survival advantages in melanoma …

Recent advances in the understanding of immunology and antitumor immune responses
have led to the development of new immunotherapies, including vaccination approaches …

Methods of harnessing the immune system to treat cancer have been investigated for
decades, but yielded little clinical progress. However, in recent years, novel drugs that allow …

Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of
lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) …